Home › Compare › LAWS vs MRK

LAWS vs MRK: Dividend Comparison 2026

LAWS yields 34.21% · MRK yields 3.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 LAWS wins by $137.5K in total portfolio value
10 years
LAWS
LAWS
● Live price
34.21%
Share price
$40.42
Annual div
$13.83
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$168.2K
Annual income
$24,922.17
Full LAWS calculator →
MRK
Merck & Co. Inc.
● Live price
3.25%
Share price
$94.80
Annual div
$3.08
5Y div CAGR
8.2%
Payout ratio
42%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.7K
Annual income
$950.29
Full MRK calculator →

Portfolio growth — LAWS vs MRK

📍 LAWS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodLAWSMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, LAWS + MRK cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
LAWS pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

LAWS
Annual income on $10K today (after 15% tax)
$2,907.66/yr
After 10yr DRIP, annual income (after tax)
$21,183.84/yr
MRK
Annual income on $10K today (after 15% tax)
$276.16/yr
After 10yr DRIP, annual income (after tax)
$807.75/yr
At 15% tax rate, LAWS beats the other by $20,376.10/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of LAWS + MRK for your $10,000?

LAWS: 50%MRK: 50%
100% MRK50/50100% LAWS
Portfolio after 10yr
$99.5K
Annual income
$12,936.24/yr
Blended yield
13.00%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

LAWS
No analyst data
Altman Z
2.0
Piotroski
5/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+35.6% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

LAWS buys
0
MRK buys
0
No recent congressional trades found for LAWS or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricLAWSMRK
Forward yield34.21% ✓3.25%
Annual dividend / share$13.83 ✓$3.08
Payout ratio50%42% ✓
1-year div growth0%5.5% ✓
5-year div CAGR0%8.2% ✓
Portfolio after 10y$168.2K ✓$30.7K
Annual income after 10y$24,922.17 ✓$950.29
Total dividends collected$120.4K ✓$6.1K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: LAWS vs MRK ($10,000, DRIP)

YearLAWS PortfolioLAWS Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$14,121$3,420.77$11,192$351.54+$2.9K → LAWS
2$19,624$4,514.39$12,524$392.70+$7.1K → LAWS
3$26,860$5,863.22$14,015$438.65+$12.8K → LAWS
4$36,241$7,500.44$15,682$489.96+$20.6K → LAWS
5$48,236$9,457.83$17,547$547.23+$30.7K → LAWS
6$63,377$11,764.56$19,632$611.16+$43.7K → LAWS
7$82,260$14,446.18$21,963$682.53+$60.3K → LAWS
8$105,541$17,523.63$24,571$762.18+$81.0K → LAWS
9$133,942$21,012.44$27,486$851.08+$106.5K → LAWS
10$168,240$24,922.17$30,745$950.29+$137.5K → LAWS

LAWS vs MRK: Complete Analysis 2026

LAWS — Stock

Lawson Products, Inc. sells and distributes specialty products to the industrial, commercial, institutional, and government maintenance, repair, and operations market. It sells its products to customers in the United States, Puerto Rico, Canada, Mexico, and the Caribbean. The company was founded in 1952 and is headquartered in Chicago, Illinois.

Full LAWS Calculator →

MRK — Healthcare

Merck is a Dividend Aristocrat with 14+ consecutive years of increases. Keytruda (pembrolizumab) is the world's best-selling cancer drug and drives exceptional cash generation. The company's oncology and vaccines pipeline provides long-term growth visibility beyond the Keytruda patent cliff in the 2030s.

Full MRK Calculator →
📬

Get this LAWS vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

LAWS vs SCHDLAWS vs JEPILAWS vs OLAWS vs KOLAWS vs MAINLAWS vs JNJLAWS vs ABBVLAWS vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.